Abstract: Objective:To discuss and analyze the factors affecting long-term survival after simultaneous treatment with 2 kinds of therapy for patients with unresectable mid and late stage liver cancer. Methods:Twenty-seven cases had unre-sectable mid and late stage liver cancer. The 10cases in stage Ⅲaccounted for37.1%;17cases in stages Ⅱ~ Ⅲaccount-ed for 62.9%; diseases affecting2 or more important organs were 24cases, accounting for 88.9%. The liver cancer focus diameters were 9.5~13cm; 1 case of liver cancer that had a focus diameter of 5.3 × 2.6 × 2.4 cm accounted for 3.7%. Treat-ments were as follows:①PCTI, ethyl alcohol and zymoplasm 2 +TACE was given1 time ( 7 cases); ②PCTI, r-INF, TNF, ethyl alcohol and zymoplasm 2 +TACE was given 1 time ( 5 cases); ③PCTI, SST and above pharmacological treatment 3 + TACE was given 1 time ( 6 cases); ④PCTI card platinum, taxus mellow, SST, r-INF, TNF, ethyl alcohol and zymoplasm3 +TACE was given 2 times (6 cases); ⑤PCTI applied above pharmacological treatment7 +TACE was given3 times (3 cases). Results: For each treatment group survival time was as follows: ①Max.426 days, min. 241 days; ②max 634 days, min. 368 days; ③max.869 days, min. 612 days; ④max 1461 days, min. 873 days; ⑤max.2,556 days (above 7 years), min. 1096 days. Conclusion:The main factors for curative effects include unresectable mid and late stage liver cancer oc-curring with hepatitis, liver cirrhosis, the portal vein hyperbarism and serious cardiopulmonary kidney disease. Moreover, the number of therapies used simultaneously, as well as the number of multiple medications, are also important factors af -fecting the cure of this disease.